Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pariser

Showing results (91-100 of 193) with videos related to

Pageof 20
Sort By:
American Heart Journal|August 1, 1984
Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenonM A Creager, K M Pariser, E M Winston, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 30, 2019
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the EditorM Gooderham, B E Elewski, D M Pariser, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline InfectionDavid M Pariser, Martin E Wendelken, Anthony M Rycerz, et al.
Journal of the American Podiatric Medical Association|September 26, 2015
Diagnosis and Management of Onychomycosis: Perspectives from a Joint Podiatry-Dermatology RoundtableBryan C Markinson, Tracey C Vlahovic, Warren S Joseph, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2021
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label studyM G Lebwohl, L Stein Gold, K Papp, et al.
Journal of the American Podiatric Medical Association|April 1, 2016
Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology RoundtableTracey C Vlahovic, Warren S Joseph, Richard K Scher, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Journal of Drugs in Dermatology : JDD|September 11, 2015
Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry RoundtableRichard K Scher, Antonella Tosti, Warren S Joseph, et al.
Pediatric Dermatology|March 10, 2020
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension studyAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
The Journal of Clinical and Aesthetic Dermatology|February 11, 2020
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity StudyDavid M Pariser, Lawrence J Green, Edward L Lain, et al.
Pageof 20

Showing results (91-100 of 193) with videos related to

Sort By:
Pageof 20
American Heart Journal|August 1, 1984
Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenonM A Creager, K M Pariser, E M Winston, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 30, 2019
Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: Letter to the EditorM Gooderham, B E Elewski, D M Pariser, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline InfectionDavid M Pariser, Martin E Wendelken, Anthony M Rycerz, et al.
Journal of the American Podiatric Medical Association|September 26, 2015
Diagnosis and Management of Onychomycosis: Perspectives from a Joint Podiatry-Dermatology RoundtableBryan C Markinson, Tracey C Vlahovic, Warren S Joseph, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2021
Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label studyM G Lebwohl, L Stein Gold, K Papp, et al.
Journal of the American Podiatric Medical Association|April 1, 2016
Diagnosis and Management of Onychomycosis Perspectives from a Joint Podiatric Medicine-Dermatology RoundtableTracey C Vlahovic, Warren S Joseph, Richard K Scher, et al.
The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.
Journal of Drugs in Dermatology : JDD|September 11, 2015
Onychomycosis Diagnosis and Management: Perspectives from a Joint Dermatology-Podiatry RoundtableRichard K Scher, Antonella Tosti, Warren S Joseph, et al.
Pediatric Dermatology|March 10, 2020
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension studyAdelaide A Hebert, Dee Anna Glaser, Lawrence Green, et al.
The Journal of Clinical and Aesthetic Dermatology|February 11, 2020
Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity StudyDavid M Pariser, Lawrence J Green, Edward L Lain, et al.
Pageof 20